Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.02 USD
Change Today 0.00 / 0.00%
Volume 0.0
GNTLF On Other Exchanges
As of 8:10 PM 11/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

60-66 Hanover Street

Fitzroy, VIC 3065


Phone: 61 3 8412 7000

Fax: 61 3 8412 7040

Genetic Technologies Limited operates as a biotechnology company. BREVAGen The company focuses on expanding its genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGen breast cancer risk assessment test, in the U.S.A. and Europe. In 2012, the company had received European CE Mark approval for BREVAGen, which would allow BREVAGen to be sold in the EU and other countries that recognise the CE Mark. Other Areas The company pursues commercial opportunities in other areas of activity: out-licensing non-coding patents worldwide; and supporting a late-stage research and development project. Genetic Testing Business The company provides paternity and related testing services in Australia. Its service testing laboratory in Fitzroy (an inner suburb of Melbourne, Victoria) is a non-Government genetic testing service provider in Australia. The company provides DNA-based individuality testing for the resolution of disputed paternity and the determination of familial relationships for immigration purposes. Other types of tests that the company could offer include Y chromosome testing, Mitochondrial DNA testing, Sibship testing, Maternity testing, DNA typing, Grandparent analysis, and Antenatal DNA testing. The company issues reports for the Family Court in Australia and provides similar services internationally for the Department of Immigration and Citizenship (DIAC). The RareCellect solution The company has developed a proprietary sampling device using materials and design features which would ensure safe, non-traumatic sampling of the optimal region of the cervix to yield fetal genetic material. Prototypes of the device have been manufactured and tested on approximately 250 women to sample fetal material during early stages of pregnancy (6 to 12 weeks). The device is protected by the U.S. provisional patent. The company has also developed processing methods that could deliver fetal cells or DNA in a form that is suitable for testing using any of the approved diagnostic methodologies. These processing methods are also covered by provisional patents. Patent Portfolio The company has 18 issued patents and 12 patent applications in the United States. The major families of patents in the portfolio include Intron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGen; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance; and RareCellect Project. Licenses and Commercial Collaborations The company has granted commercial licenses to a total of 72 licensees and 6 research licenses. Environmental Regulations The company’s operations are subject to environmental regulations under Australian State legislation. In particular, the company is subject to the requirements of the Environment Protection Act 1993. Significant Events Sale of heritage Australian Genetics business: In September 2014, the had signed a binding contract of sale for its heritage Australian Genetics business to Specialist Diagnostics Services Ltd, the wholly owned pathology subsidiary of Primary Health Care Ltd. The Australian Genetics business provides diagnostic and sequencing services encompassing Australia-only medical, forensic, paternity and animal genomic testing.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNTLF:US $0.02 USD 0.00

GNTLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $40.67 USD +0.64
Sonic Healthcare Ltd A$20.18 AUD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation GNTLF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.4x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact GENETIC TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at